BRIEF—Report bodes well for Boehringer's Stiolto Respimat

Privately-held German drugmaker Boehringer Ingelheim has welcomed the updated 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report.

Recommendations in the report propose long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) as the optimal first-line treatment option for most patients with chronic obstructive pulmonary disease (COPD), regardless of exacerbation risk.

Based on the GOLD criteria, a LAMA/LABA such as Boehringer’s Stiolto Respimat (tiotropium bromide and olodaterol) inhalation spray, is now the preferred treatment for the majority of patients with COPD.